CD19 and diffuse large B-cell lymphoma: Four of them (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel and brexucabtagene autoleucel) target CD19 for the treatment of relapsed and/or refractory (R/R) B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL), and B-cell lymphoblastic leukemia (B-ALL) [5–10].